Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is neededMark S. Butler, Peter Beyer, Stephan Harbarth et al.|Archive ouverte UNIGE (University of Geneva)|2022Cited by 221
The role of bacterial vaccines in the fight against antimicrobial resistance: an analysis of the preclinical and clinical development pipelineIsabel Frost, Peter Beyer, Mateusz Hasso-Agopsowicz et al.|The Lancet Microbe|2022Cited by 182
<i>Candida auris</i>—a systematic review to inform the world health organization fungal priority pathogens listHannah Yejin Kim, Jan‐Willem C. Alffenaar, Aiken Dao et al.|Medical Mycology|2024Cited by 60
Recent advances and challenges in antibacterial drug developmentValeria Gigante, Peter Beyer, Hatim Sati|ADMET & DMPK|2022Cited by 41
<i>Candida tropicalis</i>—A systematic review to inform the World Health Organization of a fungal priority pathogens listCaitlin Keighley, Jan‐Willem C. Alffenaar, Aiken Dao et al.|Medical Mycology|2024Cited by 39